Aldeyra Therapeutics

Aldeyra Therapeutics

ALDX· Manufacturing· Fiscal year ends in December

CEO pay in FY2023Stock -49.6% in FY2023

Todd C. Brady, M.D., Ph.D. is the CEO of Aldeyra Therapeutics and was paid $3.7M in FY2023 (Dec), up 29%.

Pay$100 in the stock at the end of FY21 → $88
CEO pay is from each Aldeyra Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives3

See all
  1. 1Todd C. Brady, M.D., Ph.D.FY2023
  2. 2Stephen G. Machatha, Ph.D.FY2025
  3. 3Michael AlfieriFY2024

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Aldeyra Therapeutics paid its one named executive on file $1.5M in FY2025 (Dec).

Name
Stephen G. Machatha, Ph.D.Chief Development OfficerNot disclosed
Todd C. Brady, M.D., Ph.D.President and Chief Executive OfficerNot disclosedNot disclosed
Michael AlfieriPrincipal Financial Officer and Principal Accounting OfficerNot disclosedNot disclosed

of each named executive, from the Summary Compensation Table of each proxy.

Peers

No disclosed peer group

No proxy on file names a pay peer group for Aldeyra Therapeutics. The peer group comes from the proxy statement, so it shows here when a proxy read has it.

Board4

See all
  • Richard H. DouglasChair · 9 yr on the boardIndependentCorporate Governance—Paid as an executive
  • Gary M. Phillips, M.D.Director · 16 yr on the boardIndependentAudit, Compensation (Chair)—Paid as an executive
  • Neal S. WalkerDirector · 12 yr on the boardIndependentCompensation—Paid as an executive
  • Nancy Miller-RichDirector · 5 yr on the boardIndependentCompensation—Paid as an executive

The board of the latest proxy (FY2025).

Activity

Filings6

See all
Proxy statementDEF 14AApr 27, 2026FY2025
Annual report10-KFeb 27, 2026FY2025
Proxy statementDEF 14AApr 25, 2025FY2024
Annual report10-KFeb 28, 2025FY2024
Proxy statementDEF 14AApr 22, 2024FY2023
Annual report10-KMar 7, 2024FY2023